GSA Capital Partners
CTSO icon

GSA Capital Partners’s Cytosorbents Corp CTSO Stock Holding History

GSA Capital Partners’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,419
Closed -$95K – 1806
2025
Q4 		$95K Buy
7,419
+1,808
+32% +$27.8K 0.01% 1534
2025
Q3 		$105K Buy
+5,611
New +$111K 0.01% 1518
2025
Q2 		– Sell
-2,652
Closed -$53K – 1802
2025
Q1 		$53K Buy
+2,652
New +$55.9K ﹤0.01% 1544
2022
Q2 		– Sell
-6,583
Closed -$420K – 1457
2022
Q1 		$420K Buy
6,583
+5,933
+913% +$425K 0.06% 655
2021
Q4 		$54K Buy
+650
New +$72.9K 0.01% 1348
2020
Q2 		– Sell
-3,793
Closed -$586K – 700
2020
Q1 		$586K Buy
3,793
+544
+17% +$54.9K 0.15% 105
2019
Q4 		$250K Buy
3,249
+1,608
+98% +$140K 0.03% 1148
2019
Q3 		$165K Buy
+1,641
New +$191K 0.02% 1211
2019
Q2 		– Sell
-844
Closed -$128K – 1487
2019
Q1 		$128K Buy
+844
New +$131K 0.01% 1309

Other funds holding CTSO

Avenir Corporation
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Skylands Capital
Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.06% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sargent Investment Group
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSA Capital Partners's CTSO Position: Q1 2026 in Review

GSA Capital Partners sold out of Cytosorbents Corp (CTSO) in Q1 2026, closing a stake of 7,419 shares — an estimated $95K sold.

GSA Capital Partners first reported a position in CTSO in Q1 2019 and held it in 9 quarters. The position peaked at $586K in Q1 2020. 48 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • GSA Capital Partners reported no remaining Cytosorbents Corp position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 7,419 Cytosorbents Corp shares in Q1 2026, an estimated $95K.
  • GSA Capital Partners first reported a position in Cytosorbents Corp in Q1 2019 and held it in 9 quarters.
  • GSA Capital Partners's Cytosorbents Corp position peaked at $586K in Q1 2020.
  • 48 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.